Cart
sales@molnova.com
ZINC05007751
CAS No. 591239-68-8
ZINC05007751( —— )
Catalog No. M28948 CAS No. 591239-68-8
ZINC05007751 is an effective inhibitor of NIMA-related kinase NEK6 (IC50 = 3.4 μM). ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity observed against NEK2, NEK7, and NEK9.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 67 | Get Quote |
|
| 5MG | 110 | Get Quote |
|
| 10MG | 177 | Get Quote |
|
| 25MG | 335 | Get Quote |
|
| 50MG | 537 | Get Quote |
|
| 100MG | 767 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameZINC05007751
-
NoteResearch use only, not for human use.
-
Brief DescriptionZINC05007751 is an effective inhibitor of NIMA-related kinase NEK6 (IC50 = 3.4 μM). ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity observed against NEK2, NEK7, and NEK9.
-
DescriptionZINC05007751 is an effective inhibitor of NIMA-related kinase NEK6 (IC50 = 3.4 μM). ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity observed against NEK2, NEK7, and NEK9.(In Vitro):In ovarian cancer cells PEO1, ZINC05007751 induced perturbation of the cell cycle. ZINC05007751 showed synergism with Cisplatin, resulting in a significant reduction of Cisplatin IC50 from 7.9 to 0.1 μM, with a combination of ZINC05007751 (44 μM) + Cisplatin (10 μM) exhibiting the greatest synergistic effect. ZINC05007751 (6 μM-190 μM; 24 hours) inhibited the growth of MDA-MB-231, PEO1, NCI-H1299, and HCT-15 with IC50 below 100 μM.
-
In VitroZINC05007751 (6 μM-190 μM; 24 hours) inhibits the growth of MDA-MB-231, PEO1, NCI-H1299 and HCT-15 with IC50 below 100?μM.ZINC05007751 induces perturbation of PEO1 cell cycle.ZINC05007751 (ovarian cancer cells PEO1) shows synergism with Cisplatin, resulting in a significant reduction of Cisplatin IC50 from 7.9 to 0.1??μM, with combination ZINC05007751 (44?μM)?+?Cisplatin (10?μM) exhibiting the greatest synergistic effect. Cell Cytotoxicity Assay Cell Line:MDA-MB-231, PEO1, NCI-H1299 and HCT-15 cells Concentration:6 μM-190 μM Incubation Time:24?hours Result:Inhibited the growth of MDA-MB-231, PEO1, NCI-H1299 and HCT-15.
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorATX (autotaxin)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number591239-68-8
-
Formula Weight304.305
-
Molecular FormulaC18H12N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 8.33 mg/mL (27.37 mM)
-
SMILESCC1=C(C#N)C(O)=NC(=O)\C1=C/c1ccc(o1)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.LEE, Dae Yon, et al. NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME. Patent O2018212534A1
molnova catalog
related products
-
AS1940477
A potent, selective, orally active p38α/p38β inhibitor with IC50 of 11.2/36.5 nM respectively, with no effect on p38γ and δ isoforms (IC50>1 uM).
-
HPK1-IN-7
HPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
-
dencichine
Dencichine is a neurotoxic agent. Dencichine is a haemostatic agent, the hemostatic effect relates to modulation of the coagulation system, platelet aggregation and fibrinolytic system.
